Post-earnings recap
Reported
Fri, Mar 8, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Rhythm Pharmaceuticals reported a loss per share of $0.74, which was expected but not detailed against consensus estimates. Despite the lack of revenue details and guidance, the stock rose 1.31%, indicating some investor optimism about the company's future product developments and strategies.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach regarding future performance. They highlighted ongoing efforts to develop their product offerings.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their product pipeline.